Analysis of the effect of immunosuppressive therapy on the progression of chronic kidney disease with mesangioproliferative nephritis

Abstract

Aim. To assess the effect of immunosuppressive cyclophosphamide therapy and its regimens on the rate of progression of chronic kidney disease in mesangioproliferative glomerulonephritis.

Methods. 72 patients with mesangioproliferative glomerulonephritis and indications for immunosuppressive therapy with disease activation were included in the comparative analysis: 56 patients received cyclophosphan in conventional doses (26 patients with daily or every other day, 30 patients with in pulse mode 1 time per month), and 16 patients did not receive cyclophosphan. Duration of the disease before observation ranged from 0 to 33.58 years, a median follow-up was 6.00 (interquartile range 1.63–13.17) years, and after observation from 0 to 5 years with the median follow-up was 2.00 (1.00–3.50) years. The examination included nephrobiopsia with a morphological diagnosis, activity index/sclerosis, and glomerulonephritis progression rate for decreased glomerular filtration rate (ml/min/1.73 m² per year).

Results. The progression rate of chronic kidney disease was higher in the group of patients not receiving immunosuppressive therapy, 5.57 (3.27–7.95) ml/min/1.73 m2 per year compared with of the treated patients group, 3.05 (2.04–6.78) ml/min/1.73 m2 per year (p=0.040). There were no differences in the rate of decrease in glomerular filtration rate between groups depending on the treatment regimen: 4.86 (2.12–6.77) ml/min/1.73 m2 per year with regular and 3.67 (2.04– 6.91) ml/min/1.73 m2 per year with a pulse mode (p=0.720). The rate of glomerulonephritis also did not differ significantly: 1.0 (1.0–2.0) and 2.0 (1.0–2.0) relapses over 5 years, respectively (p=0.691) in both treatment regimens.

Conclusion. The treatment of patients with mesangioproliferative glomerulonephritis with cyclophosphane, in combination with prednisone or without it, regardless of the treatment regimen induces a slowdown in the progression of chronic kidney disease, improving the long-term prognosis and without affecting the frequency of relapses of the disease.

Keywords

mesangioproliferative glomerulonephritis / cyclophosphamide / modes of therapy / rate of progression of chronic kidney disease

References

[1] Bikbov B.T., Tomilina N.A. The contingent and treatment quality indicators in patients on replacement therapy of end stage renal disease in the Russian Federation in 1998–2013 years. Nefrologiya i dializ. 2016; 18 (2): 98–164. (In Russ.)

[2] Бикбов Б.Т., Томилина Н.А. Состав больных и показатели качества лечения на заместительной терапии терминальной хронической почечной недостаточности в Российской Федерации в 1998–2013 гг. Нефрол. и диализ. 2016; 18 (2): 98–164.

[3] Jo Y.I., Na H.Y., Moon J.Y. et al. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial. Korean J. Intern. Med. 2016; 31 (2): 335–343. DOI: 10.3904/kjim.2014.266.

[4] Kawasaki Y. The pathogenesis and treatment of IgA nephropathy. Fukushima J. Med. Sci. 2008; 54 (2): 43–60. DOI: 10.5387/fms.54.43.

[5] Shilov E.M., Smirnov A.V., Koz­lovskaya N.L. Nefrologiya. Klinicheskie rekomendatsii. (Nephrology. Clinical guideline.) Moscow: GEOTAR-­Media. 2016; 816 p. (In Russ.)

[6] Шилов Е.М., Смирнов А.В., Козловская Н.Л. Нефрология. Клинические рекомендации. М.: ­ГЭОТАР-­Медиа. 2016; 816 с.

[7] Berthoux F.C., Mohey H., Afiani A. Natural history of primary IgA nephropathy. Semin. Nephrol. 2008; 28 (1): 4–9. DOI: 10.1016/j.semnephrol.2007.10.001.

[8] Shilov E.M., Tareeva I.E., Ivanov A.A. et al. The course and prognosis of mesangial proliferative glomerulonephritis. Terapevticheskiy arkhiv. 2002; 74 (6): 11–18. (In Russ.)

[9] Шилов Е.М., Тареева И.Е., Иванов А.А. и др. Течение и прогноз мезангиопролиферативного гломерулонефрита. Терап. арх. 2002; 74 (6): 11–18.

[10] Kidney disease: Improving global outcomes (­KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Intern. Suppl. 2012; 2: 139–274. DOI: 10.1038/kisup.2012.9.

[11] Li P.K., Leung C.B., Chow K.M. et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a ­double-blind, randomized, placebo-controlled study. Am. J. Kidney Dis. 2006; 47 (5): 751–760. DOI: 10.1053/j.ajkd.2006.01.017.

[12] Kidney Disease: Improving Global Outcomes (­KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013; 3 (1): 1–150. DOI: 10.1038/kisup.2012.73.

[13] McCarthy D.D., Kujawa J., Wilson C. et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J. Clin. Invest. 2011; 121 (10): 3991–4002. DOI: 10.1172/JCI45563.

[14] Eftimovska N., Stojceva-Taneva O., Polenako­vic M. Slow progression of chronic kidney disease and what it is associated with. Prilozi. 2008; 29 (1): 153–165. PMID: 18709007.

[15] Hirahashi J., Hanafusa N., Wada T. et al. Aspirin and eicosapentaenoic acid may arrest progressive IgA neph­ropathy: a potential alternative to immunosuppression. Intern. Med. 2015; 54 (18): 2377–2382. DOI: 10.2169/internalmedicine.54.4623.

[16] Hirahashi J. Omega-3 polyunsaturated fatty acids for the treatment of IgA nephropathy. J. Clin. Med. 2017; 6 (7): 70. DOI: 10.3390/jcm6070070.

[17] Jalalah S.M. IgG glomerulonephritis: a morpholo­gic study of a rare entity. Saudi J. Kidney Dis. Transpl. 2009; 20 (5): 798–801. PMID: 19736476.

[18] Chen X., Chen P., Cai G. et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua. Yi. Xue. Za. Zhi. 2002; 82 (12): 796–801. PMID: 12126522.

[19] Tumlin J.A., Lohavichan V., Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclopho­sphamide. Nephrol. Dial. Transplant. 2003; 18 (7): 1321–1329. DOI: 10.1093/ndt/gfg081.

[20] Haas M., Verhave J.C., Liu Z.H. et al. A Multicenter Study of the predictive value of crescents in IgA neph­ropathy. J. Am. Soc. Nephrol. 2017; 28 (2): 691–701. DOI: 10.1681/ASN.2016040433.

[21] Myllymaki J., Saha H., Mustonen J. et al. IgM nephro­pathy: clinical picture and long-term prognosis. Am. J. Kidney Dis. 2003; 41 (2): 343–350. DOI: 10.1053/ ajkd.2003.50042.67.

[22] Sigitova O.N., Kim T.Yu., Salmakova A.V. Flow features of immunoglobulin a nephropathy depending on activity/risk of progression and influence of pathogene­tic therapy. BioNanoScience. 2019; 9 (2): 495–501. DOI: 10.1007/s12668-019-0594-z.

RIGHTS & PERMISSIONS

Sigitova O.N., Kim T.Y., Sineglazova A.V., Kamasheva G.R., Nadeeva R.A.